Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline. 

What is ORI-001? 

ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Phase I/II trial to start in 2023.   

Official comments 

“The acquisition of Origimm further broadens our vaccines R&D pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults,” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur. “Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome and skin immunology. We look forward to unlocking the full potential of this candidate”. 

“We are looking forward to combining our expertise and strengths to continue developing innovative solutions for prevention and treatment of the skin microbiome-associated diseases, such as common acne” said Sanya Selak, Founder & CEO/CSO of Origimm. “Together with such a strong partner like Sanofi, we will strive to creating a paradigm shift in treatment of skin diseases and many other microbiome-associated disorders and infections, for which current medical solutions are inadequate.” 


Acne is a widespread and stigmatising condition for millions of people globally, causing substantial psychological burden for teenagers but also adults – over 10% of them still experiencing acne after age 501. The Cutibacterium acnes bacterium plays a central role in the development of moderate to severe acne. There is today no satisfactory treatment against acne combining high efficacy and acceptable safety. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free